Baxter(US:BAX) Globenewswire·2025-11-20 21:26Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud related to the company's product malfunctions and inadequate responses to safety concerns [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and fatalities linked to these defects [2]. - The company's attempts to address these issues through customer alerts were deemed insufficient, as design flaws persisted and continued to harm patients [2]. - There was an increased risk that customers would be advised to withdraw existing Novum LVPs from service, and Baxter might halt all new sales of these pumps [2]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were alleged to be materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who experienced losses in Baxter International, Inc. during the specified period have until December 15, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].